Following the positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole, Lundbeck hosted a conference call and webcast for investors and analysts on June 27 at 10:00 AM CEST to briefly discuss the topline results of the trial.
Watch the replay of the webcast here